A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients with liver cancer.
The following abbreviations were used in the Adverse Event section:
Inclusion Criteria:
Exclusion Criteria:
Bueno Aires, Ciudad Auton. de Buenos Aires C1417DTB, Argentina
East Bentleigh, Victoria 3165, Australia
Bruxelles - Brussel, 1070, Belgium
Bruxelles - Brussel, 1090, Belgium
Bruxelles - Brussel, 1200, Belgium
Santiago Región Metropolitana, Chile
Haidari, Attica 12462, Greece
Zrifin, Israel 70300, Israel
Wellington South, 6001, New Zealand
Comas Lima, Peru
Craiova Dolj, 200642, Romania
Tolgliatti, Russia
Cruces/Barakaldo, Bilbao 48903, Spain